2025 HCPCS code J2353
(Active) Effective Date: N/A Drugs Administered Other than Oral Method - Drugs, Administered by Injection Feed
Injection, octreotide, depot form for intramuscular injection, 1 mg.
Medical necessity must be established based on the patient's diagnosis and the specific condition being treated with octreotide. Payer guidelines may also apply.
The provider administers octreotide to treat conditions such as acromegaly and diarrhea caused by cancerous tumors. This code represents the drug supply only, not administration.
In simple words: Octreotide is a man-made protein used to treat various conditions by lowering certain substances in the body, such as insulin, glucagon, and growth hormone. This code is for 1 mg of the long-acting version given as a shot into a muscle.
Octreotide is a synthetic protein with properties similar to the hormone somatostatin. One unit of this code represents 1 mg of octreotide in depot form for intramuscular injection. The depot form allows for prolonged absorption at the injection site.
Example 1: A patient with acromegaly receives a 20 mg intramuscular injection of octreotide every 4 weeks., A patient with a carcinoid tumor experiencing carcinoid syndrome receives a 10 mg intramuscular injection of octreotide every 4 weeks., A patient with a VIP-secreting tumor receives a 30 mg intramuscular injection of octreotide every 4 weeks.
Documentation should include the diagnosis, dosage, route of administration, and medical necessity for the use of octreotide.
** This is a generic drug. Brand names include Sandostatin LAR Depot®. Check payer guidelines for coverage of drug administration.
- Specialties:Endocrinology, Oncology, Gastroenterology
- Place of Service:Office, Inpatient Hospital